Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,808.41
-16.6097-0.91%
Number of Gainers:7
Number of Losers:12
Number of Flat:- -
PE:- -
High:1,831.56
Open:1,825.61
Low:1,802.81
Close:1,824.99
Volume:59.53M
Turnover:4.89B
Market Cap:1.47T
Float Cap:1.44T

Loading ...

Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC

TIPRANKS
·
Sep 29

Stocks to Watch: Summit Therapeutics, Sangoma, Navitas

Dow Jones
·
Sep 29

Nanoviricides Q4 EPS $(0.10), Inline

Benzinga Earnings
·
Sep 29

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

TIPRANKS
·
Sep 29

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

BioNTech CEO Uğur Şahin Disposes of USD 6,090,748 in Common Shares

Reuters
·
Sep 29

NanoViricides FY26 Net Loss Narrows 13% to $8.22 Million; Revenue Remains no Revenue

Reuters
·
Sep 29

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Reuters
·
Sep 29

Market Chatter: BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts

MT Newswires Live
·
Sep 29

AstraZeneca Advances Fixed-Dose Cholesterol Combo With Completed Phase I Bioavailability Study

TIPRANKS
·
Sep 29

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 29

Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

MT Newswires Live
·
Sep 28

BioNTech to Proceed with Site Closures After Failing to Find Buyer

Dow Jones
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

NanoViricides Starts Phase II DRC Trial of Oral NV-387 Gummies in Bundibugyo Ebola Patients

Reuters
·
Sep 28

Humacyte Adds Scott Coward to Board, Names Him to Audit Committee

Reuters
·
Sep 28

Xilio Therapeutics Names Yariv Houvras Chief Medical Officer

Reuters
·
Sep 28

Pfizer to Present Phase 3 SigVie-002 Survival Data for Sigvotatug Vedotin in Previously Treated NSCLC at ESMO 2026

Reuters
·
Sep 28

Berenberg Bank Sticks to Its Hold Rating for Bilfinger (0NRG)

TIPRANKS
·
Sep 28

Abbott Study Links CGM Use in Type 2 Diabetes Patients on Basal Insulin to 45% Lower 12-Month Mortality Risk

Reuters
·
Sep 28